Journal: Translational Oncology

Article Title: Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma

doi: 10.1016/j.tranon.2022.101413

Figure Lengend Snippet: Antibodies used in Flow cytometry analysis

Article Snippet: CD112-PE , R2.525 , Miltenyi Biotec (CA,USA).

Techniques: Flow Cytometry, Control, Staining

Journal: Translational Oncology

Article Title: Novel IL-15 dendritic cells have a potent immunomodulatory effect in immunotherapy of multiple myeloma

doi: 10.1016/j.tranon.2022.101413

Figure Lengend Snippet: IL-15 mDCs showed the enhanced cytotoxicity by generation of potent autologous cytotoxic T lymphocytes, CIK cells, and NK cells against primary autologous myeloma cells (paired). (A) We analyzed CD138 + primary myeloma cells isolated from bone marrow aspiration samples of newly diagnosed multiple myeloma patients to assess the expression levels of MHC class I, MICA, MICB, ULBP1, ULBP2/5/6, HLA-E, CD38 (n = 12), and CD112, CD155, ICAM-1 and PD-L1 (n = 5) using flow cytometry. ( B) We measured the expression of the degranulation marker CD107a in CTLs, CIK cells, and NK cells generated by mDCs against primary autologous myeloma cells. ( C) The killing capacity of activated lymphocytes by mDCs against primary autologous myeloma cells was investigated using an LDH-release cytotoxicity assay without or with anti-MHC class I mAb (n = 3). The data indicate that CLTs, CIK cells, and NK cells generated by the IL-15 mDCs (6 days) and IL-15 mDCs (8 days) groups exhibited stronger cytotoxicity than those of the conventional mDCs group. Data are representative from three independent experiments. *P < 0.05; ** P < 0.01; *** P < 0.001 (One-way ANOVA, multiple comparisons test: Tukey for B. Multiple t tests – one per row for C).

Article Snippet: CD112-PE , R2.525 , Miltenyi Biotec (CA,USA).

Techniques: Isolation, Expressing, Flow Cytometry, Marker, Generated, Cytotoxicity Assay

Journal: Cell Death & Disease

Article Title: Deciphering the tumor immune microenvironment of imatinib-resistance in advanced gastrointestinal stromal tumors at single-cell resolution

doi: 10.1038/s41419-024-06571-3

Figure Lengend Snippet: a Cell communication analysis on TIGIT-NECTIN2 and BTLA-TNFRSF14 pair between different cell types in imatinib resistant and sensitive patients respectively. Expression of NECTIN2 ( b ), BTLA ( c ) and TNFRSF14 ( d ) in each cell type in imatinib resistant and sensitive patients respectively. e IHC analysis of NECTIN2, BTLA and TNFRSF14 between imatinib resistant (upper) and sensitive (bottom) patients. f Schematic diagram of the unique tumor-immune microenvironment of imatinib-resistance in advanced GIST.

Article Snippet: Finally, two experienced pathologists independently evaluated staining results for Foxp3 (Servicebio, GB11093), BTLA (Boster, A03149), TNFRSF14 (Affinity, AB2838686) and NECTIN2 (Boster, A08081-2).

Techniques: Expressing